for quarter ended June 30, 2026.
RESULTS
● No Immediate Change
LOW RISK
📅 Filed on BSE: 13 Jul 2026, 03:20 PM IST · BSE ID: 9876bdc7-dd6c-4e55-aba6-24c024165c86
View Original BSE Filing (PDF)
💡
In Simple Terms
The company confirmed all its shares are electronic and no paper share conversions happened last quarter.
🤖 AI Summary
- Valiant Laboratories filed its Regulation 74(5) certificate for the quarter ended June 30, 2026.
- All securities of Valiant Laboratories are held in dematerialized form.
- No requests for dematerialization or cancellation of securities were received during the June 2026 quarter.
- MUFG Intime India Private Limited, the Registrar and Share Transfer Agent, provided the confirmation.
- The certificate affirms compliance with SEBI (Depositories and Participants) Regulations, 2018.
🏢 How This Affects the Company
The company's RTA, MUFG Intime India Private Limited, confirmed no physical share handling requests for the quarter ended June 30, 2026.
Compliance with Regulation 74(5) reduces regulatory risk related to share transfer and dematerialization processes.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this filing.
👤
Who Is Affected
Shareholders holding Valiant Laboratories shares in dematerialized form are not directly affected, as no changes in share status or processing were reported for the quarter ended June 30, 2026.
🔍
Management Signal
The filing indicates management's adherence to ongoing regulatory compliance requirements as per SEBI regulations for depositories.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Next quarterly financial results — check for business performance updates.
Subsequent Regulation 74(5) filings — confirm continued compliance.
Any material event disclosures under Regulation 30 LODR.
LOW RISK
This is a routine compliance filing with no associated financial or operational risks indicated.
💡 Investor Takeaway
Valiant Laboratories confirmed compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026. All company securities remain in dematerialized form, with no requests for dematerialization received by the RTA.
⚖️ Strengths & Concerns
✅ Positives
- The company maintains full dematerialization of its securities, simplifying record-keeping and share transfers.
- Compliance with Regulation 74(5) for Q1 FY27 indicates adherence to regulatory requirements for depositories and participants.
📅 Company Track Record
Valiant Laboratories' recent audited standalone net profit for FY26 was Rs. 554.82 Lakhs, representing a significant turnaround. The company was incorporated on CIN: L24299MH2021PLC365904, indicating a relatively recent establishment in 2021.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What is the purpose of Valiant Laboratories' Regulation 74(5) filing?
The filing confirms compliance with SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026, regarding securities dematerialization.
Are Valiant Laboratories' securities held in dematerialized form?
Yes, the filing confirms that all securities of Valiant Laboratories are held in dematerialized form.
Were any dematerialization requests received by Valiant Laboratories in Q1 FY27?
No, the certificate states that no requests for dematerialization or cancellation of securities were received during the quarter ended June 30, 2026.
Questions based on this BSE filing only. For information purposes.